Tiotropium
- Generic Name
- Tiotropium
- Brand Names
- Inspiolto Respimat, Spiriva, Spiriva Respimat, Stiolto
- Drug Type
- Small Molecule
- Chemical Formula
- C19H22NO4S2
- CAS Number
- 186691-13-4
- Unique Ingredient Identifier
- 0EB439235F
- Background
Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.
Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than ipratropium.
Tiotropium was granted FDA approval on 30 January 2004.
- Indication
Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD. A combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of COPD. A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 12 or more years old. A tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 6 or more years old.
- Associated Conditions
- Asthma, Bronchitis, Bronchoconstriction, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Exacerbation of COPD
- Associated Therapies
- -
A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 260
- Registration Number
- NCT01395888
- Locations
- 🇺🇦
GSK Investigational Site, Yalta, Ukraine
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2017-11-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 163
- Registration Number
- NCT01372410
- Locations
- 🇺🇸
GSK Investigational Site, Union, South Carolina, United States
Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- James J. Peters Veterans Affairs Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT01355991
- Locations
- 🇺🇸
Kessler Institute for Rehabilitation, West Orange, New Jersey, United States
🇺🇸James J. Peters VA Medical Center, Bronx, New York, United States
Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 76130
- Registration Number
- NCT01331694
Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT01309139
- Locations
- 🇩🇪
1298.2.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Effects of Tiotropium on Walking Capacity in Patients With COPD
- Conditions
- Interventions
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2011-03-02
- Lead Sponsor
- Laval University
- Target Recruit Count
- 33
- Registration Number
- NCT01307189
- Locations
- 🇨🇦
Centre de recherche de l'IUCPQ, Quebec, Canada
Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2013-03-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 85
- Registration Number
- NCT01294787
- Locations
- 🇪🇸
Novartis Investigative Site, Malaga, Spain
Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 1070
- Registration Number
- NCT01290874
- Locations
- 🇺🇸
G.A. Carmichael F.H.C., Canton, Mississippi, United States
🇺🇸Edward Waters College Medical Center (Mayo), Jacksonville, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2013-12-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT01285492
- Locations
- 🇯🇵
Novartis Investigative Site, Wakayama, Japan
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2010-09-15
- Last Posted Date
- 2013-09-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2144
- Registration Number
- NCT01202188
- Locations
- 🇯🇵
Novartis Inverstigative Site, Iwata, Japan
🇭🇺Novartis INvestigative Site, Balassagyarmat, Hungary
🇦🇺Novartis Investigative site, New lambton, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.